Biotech | April 25, 2022
CanSinoBIO rebrands to reflect commitment to life sciences research
This is the first major brand refresh of CanSinoBIO since its inception in 2009
This is the first major brand refresh of CanSinoBIO since its inception in 2009
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
The Phase 3 trial will be conducted under the auspices of the first Regenerative Medicine Advanced Therapy (RMAT) designation approved by the USFDA for an EV therapeutic
Support for biologics manufacturability and Industry 4.0 initiatives
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
Pharmapack trends are a key barometer of global device and packing opportunities in 2022
Makrolon polycarbonate is key to needle-free injections that can stand up to sterilization
MilliporeSigma to become the first company to offer a fully integrated ecosystem for advanced process technologies
New high-throughput, no-wash assays contribute to the development, manufacture and quality control of safer, more effective biotherapeutics
Subscribe To Our Newsletter & Stay Updated
